A Mitochondria-Targeted Caffeic Acid Derivative Reverts Cellular and Mitochondrial Defects in Human Skin Fibroblasts from Male Sporadic Parkinson’s Disease Patients

Dr. Paulo J. Oliveira from University of Coimbra, Portugal will join the Targeting Mitochondria 2021 congress and will present a talk entitled A Mitochondria-Targeted Caffeic Acid Derivative Reverts Cellular and Mitochondrial Defects in Human Skin Fibroblasts from Male Sporadic Parkinson’s Disease Patients".

Dr. Oliveira highlighted: "We are developing a lead mitochondria-targeted hydroxycinnamic acid derivative with potential use in different diseases with a mitochondrial dysfunction component.  This talk will focus on our recent study investigating the effects of our novel molecule on skin fibroblasts from sporadic Parkinson's Disease (PD) patients. Our data shows a positive impact of this molecule on mitochondrial function and redox signaling, paving the way to further in vivo studies to validate this molecule in a PD model".

Targeting Mitochondria 2021 Congress
October 27-29, 2021
Berlin, Germany & Virtual Congress
www.targeting-mitochondria.com